BRAF and neoplasm: Mutations in BRAF are known to induce senescence in tumor cells in serrated lesions, suggesting that type A1 TSAs may maintain the stable status of tumor cells owing to BRAF mutations and subsequent cellular senescence in TSA cells [25], promoting the progression of TSA.